CDKN2A - melanoma-pancreatic cancer syndrome ¹
This test is available for the following conditions:
- Conditions > Skin > Melanoma-pancreatic cancer syndrome
- Conditions > Oncogenetics > Melanoma-pancreatic cancer syndrome
This product is also part of the following panels:
- panel Melanoma, basic (CDKN2A, CDK4, MITF p.(Glu318Lys)¹
- panel Melanoma, basic (CDKN2A, CDK4, MITF p.(Glu318Lys)¹
- panel Melanoma, extensive (CDKN2A, CDK4, MITF p.(Glu318Lys), BAP1, POT1, TERT promoter)¹
- panel Melanoma, extensive (CDKN2A, CDK4, MITF p.(Glu318Lys), BAP1, POT1, TERT promoter)¹
- WES hereditary cancer (100.0% *)
- WES Mendelian inherited disorders (100.0% *)
- WES skin disorders¹ (100.0% *)
* % of the coding region of this gene has a coverage of >20x. (Without % information : This is a non-coding gene for which coverage statistics could not be determined)
Turnaround time
Complete analysis: 8 weeks / Targeted analysis: 4 weeks
Method
- Sequence analysis of all coding exons and flanking intron-exon boundaries
OMIM:
600160
Performing laboratory: Maastricht UMC+
Authorized material(s): EDTA blood, Isolated DNA, Buccal mucous membrane